The search for a better Faslodex continues
Selective oestrogen degraders, or Serds, remain in focus as a key period for reporting clinical data approaches.
Oncopeptides gives with one hand and takes away with the other
Upon review Pepaxto beats Pomalyst on progression-free survival, but new overall survival data trigger clinical hold and threaten the programme.
Why Glaxo should buy Biohaven
And four other potential targets that could make sense for the beleaguered group.
Venture investors still love drug developers
Biopharma scores a $5bn quarter as another big year builds for venture financing.
Smaller companies set for third-quarter catalysts
The third quarter will see important data for Travere, Radius and Sio Gene, among other small developers.
